Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 randomized double-blind placebo-controlled study of single ascending doses of ABBV-47D11 in hospitalized adults with COVID-19
NL-OMON50807Phase 1Withdrawn
- Sponsor
- AbbVie Inc.
- Start
- Dec 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing ABBV-47D11 with Placebo (2 arms). Primary endpoints: Number of participants with study-drug related Grade 3 or higher adverse events and Number of participants with study-drug related Grade 3 or higher infusion-related reactions. Planned start Dec 2020; status: withdrawn.
02
Drugs
ABBV-47D11
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NL-OMON50807.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50807.